ArticleAngewandte Chemie (International ed. in English)2025
New Transferrin Receptor-Targeting Conjugate Effectively Delivers DNA to Mouse Brain.
Article in Angewandte Chemie (International ed. in English), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Overcoming the blood‒brain barrier: nanomedicine strategies for targeted delivery and multimodal therapy in Alzheimer's disease.Drug delivery · 2026Review
- Tuning protein corona on nucleic acid nanodrugs for targeted delivery.Acta pharmaceutica Sinica. B · 2026Review
- Ligand-modified multifunctional liposome-based targeted delivery platform: a multimodal cancer combination therapy strategy.Theranostics · 2026Review
- New Transferrin Receptor-Targeting Conjugate Effectively Delivers DNA to Mouse Brain.Angewandte Chemie (International ed. in English) · 2025Article
- Strategies for delivering drugs across the blood-brain barrier for the treatment of neurodegenerative diseases.Frontiers in drug delivery · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Delivery across the blood-brain barrier (BBB) is one of the most challenging tasks for modern biopharmaceutics. Many attempts have been taken, with only low delivery efficacies achieved so far. We report a new transferrin receptor-targeting (TfR) RNA aptamer conjugated to DSPE lipid that leads to an unprecedented effective uptake in the brain, with brain-to-serum ratios up to 6.5 in mice. This result is superior to recently published values of < 1 for antibody conjugates and nanovesicles, pointing to a successful combined effect of the increased lipophilicity and TfR targeting with the new RNA aptamer that our conjugate provides. Using fluorescence whole body imaging, polymerase-chain reaction (PCR) and fluorescence in situ hybridization, we confirm that the new conjugate delivers high amounts of DNA oligonucleotide to brains of Balb/cJ mice, and it is effective in human cells. There is no acute toxicity as verified with histopathological assessment of mice organs. The combination of properties demonstrated by our new conjugate makes it a highly potent delivery tool that can be applied in therapy of brain diseases incl. glioblastoma, neurogenerative diseases, and a broad range of brain infections.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.